Artificial Pancreas Device Systems

Artificial Pancreas Device Systems

Global Artificial Pancreas Device Systems Market to Reach US$1.5 Billion by 2030

The global market for Artificial Pancreas Device Systems estimated at US$459.0 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.8% over the analysis period 2023-2030. Threshold Suspended Device Systems, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Control-to-Target (CTT) Systems segment is estimated at 19.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$126.9 Million While China is Forecast to Grow at 17.8% CAGR

The Artificial Pancreas Device Systems market in the U.S. is estimated at US$126.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$230.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Artificial Pancreas Device Systems Market - Key Trends and Drivers Summarized

How Are Artificial Pancreas Device Systems Transforming Diabetes Care?

Artificial pancreas device systems (APDS) have emerged as a groundbreaking advancement in diabetes care, particularly for those with Type 1 diabetes who require precise and continuous insulin management. These systems automate the process of insulin delivery by integrating continuous glucose monitors (CGMs) with insulin pumps and advanced algorithms, closely mimicking the function of a healthy pancreas. By maintaining glucose levels within a target range with minimal manual intervention, APDS significantly lighten the burden of diabetes management, leading to improved patient outcomes and an enhanced quality of life. As technology continues to advance, these systems are being hailed as the future of diabetes treatment, offering unmatched precision and control compared to traditional insulin administration methods.

What Technological Innovations Are Driving the Success of Artificial Pancreas Systems?

The success of artificial pancreas device systems has been largely driven by continuous technological innovations, particularly in sensor accuracy, algorithm sophistication, and seamless device integration. Recent improvements in CGM technology have resulted in sensors that provide highly accurate and reliable glucose readings with fewer calibrations, a critical component for the effectiveness of APDS. Advanced algorithms capable of predicting glucose trends and automatically adjusting insulin delivery in real-time have made these systems even more responsive to the body’s needs. The development of dual-hormone systems that administer both insulin and glucagon represents a promising leap forward, offering enhanced glucose control during exercise, illness, or other challenging conditions. These innovations have not only improved the efficacy of APDS but also made them more user-friendly and comfortable for everyday use.

What Emerging Trends Are Fueling the Adoption of Artificial Pancreas Systems?

A number of emerging trends are fueling the widespread adoption of artificial pancreas device systems, reflecting a broader shift toward more personalized and accessible diabetes care. The push for personalized medicine has led to the development of APDS tailored to the unique needs of individual patients, making these systems more effective and user-friendly. The rise of telemedicine and remote monitoring capabilities has also contributed to the growing popularity of APDS, as these technologies enable continuous glucose monitoring and insulin adjustments without the need for in-person visits. Additionally, expanded health insurance coverage for diabetes management devices is making APDS more accessible to a wider audience. The increasing prevalence of Type 1 diabetes, especially among younger populations, is further driving the demand for these systems as a means to improve long-term health outcomes and minimize the risks associated with poor glucose control.

Which Factors Are Fueling the Growth of the Artificial Pancreas Device Systems Market?

The growth in the artificial pancreas device systems market is fueled by several key factors that are shaping the future of diabetes management. The rising global prevalence of diabetes, particularly Type 1 diabetes, has created an urgent need for more precise and effective glucose management solutions. Technological advancements in continuous glucose monitoring, insulin pumps, and AI-driven algorithms have significantly improved the performance and reliability of APDS, making them more attractive to both patients and healthcare providers. The expansion of telehealth services and the increasing adoption of wearable health technologies are further boosting the market by providing more convenient and effective diabetes management options. Additionally, the growing emphasis on pediatric diabetes care is driving the development of more user-friendly and less invasive devices, broadening the market’s potential. As healthcare systems continue to prioritize value-based care, the ability of APDS to improve patient outcomes and reduce long-term diabetes management costs is expected to further propel the market’s growth.

Select Competitors (Total 47 Featured) -

• Beta Bionics, Inc.
• Bigfoot Biomedical, Inc.
• Johnson & Johnson
• Medtronic PLC
• Pancreum, Inc.
• Tandem Diabetes Care, Inc.
• TypeZero Technologies LLC

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.